1.	Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 116428, 2012-003438-18, NCT01767467
2.	Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MSCMI-40-2003, MSCMI 40/2003, EU-20913, NCT00937183
3.	Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 74 Sponsor: NCI Protocol IDs: 080051, 08-C-0051, NCT00923910
4.	Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 65 Sponsor: Pharmaceutical / Industry Protocol IDs: BP-HM-001, NCT01744223
5.	Immunization Against Tumor Cells in Sezary Syndrome Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FD-R-002545-01, NCT00099593
6.	Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: FAV-ID-70, FAV-ID-LYM-31, NCT00258336
7.	Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL Phase: Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: NCI Protocol IDs: LYMNHL0040, 96940, LYMNHL0040-BMT212, 5089, NCT00490529
8.	Idiotypic Vaccination for Follicular Lymphoma Patients Phase: Phase II Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: CUN-90-2006, NCT00530140
9.	Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SCCC-102007-035, 102007-035, SCCC-02F07, NCT00621036
10.	Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma Phase: Phase I Type: Treatment Status: Active Age: 40 and over Sponsor: Other Protocol IDs: 06-275, NCT00487305
11.	Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 07-100, MSKCC-07100, NCT00561756
12.	Host Dendritic Cells in Allograft Patients Phase: Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 08-0906, NCT00935597
13.	Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma Phase: Phase I Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: 2009-0465, NCT01209871
14.	Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: NCI, Other Protocol IDs: LS1081, NCI-2010-02003, 10-003023, NCT01239875